Skip to main content
OpenTrials
Completed

NCT Number: NCT05522296

Break-through Infection Following Mpox vaccinatIon

The purpose of this study is to assess the protection of smallpox preexposure vaccination against infection with mpox in real-world individuals with risk factors for mpox.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Male

Study type

Observational

Primary location

Hospital Clínico San Borja Arriarán, Santiago, Santiago Metropolitan, Chile

Loading trial locations.

About this study

A Target Trial Emulation study that tries to emulate the sequential specification of a target trial will be conducted measuring and controlling confounders when there is a common cause of vaccination and outcome event.

Participants will be provided with a Quick response (QR) code to access the RedCap study platform, which will guide them to the enrolment process. If the participant accepts and meets all the inclusion and none of the exclusion criteria, they will be directed to a baseline survey to self-collect sociodemographic data and information regarding risk factors, sexual behaviour, vaccination, and exposure to mpox.

Newly vaccinated participants will be matched 1:1 to unvaccinated controls. The matching will be performed based on the site of recruitment, and self-reported baseline sexual health and practices. Vaccinated and unvaccinated participants will be matched on variables associated with the probability of infection.

Follow-up will include regular surveys every month from the index date (i.e., enrolment date in the unvaccinated group, or vaccination date for the vaccinated group), to collect data on change on risk factors, sexual behaviour in the past month, vaccination status, and exposure to mpox. The participant will be asked to self-report if they develop symptoms suggestive of mpox, and the study platform will direct them to a specific mpox infection survey.

For each participant, follow-up will end at the earliest of the following events: mpox infection, voluntary withdraw, or the end of the study period. A health record review will be conducted to corroborate the diagnosis of new cases and to provide validity to the self-report.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Individuals aged 18 years or older.
  • Individuals with general risk factors for mpox infection, as currently defined by the local guidelines for vaccination. These risk factors include at least one of the following items:
  • Individual-reported use of HIV pre-exposure prophylaxis (PrEP).
  • Individual-reported chemsex practices
  • Individual-reported multiple sexual partners.
  • Individuals with a history of a sexually transmitted infection (STI) in the past year.
  • Individuals living with HIV infection.
  • Signature of informed consent.

Exclusion criteria

  • Unable to provide signature of informed consent.
  • Past infection with monkeypox.
  • Past smallpox vaccination.

Treatment and study plan

Mpox Vaccine

Drug

Vaccination with smallpox and mpox vaccine (Live Modified Vaccinia Virus Ankara)

Primary outcomes

  1. Polymerase chain reaction (PCR)-confirmed mpox infection

    Time frame: From 14 days after the index date to twelve months after the index date

    Mpox PCR positivity in participants with mpox infection symptoms

Secondary outcomes

  1. Polymerase chain reaction (PCR)-confirmed mpox infection

    Time frame: From immediately after the index date to twelve months after the index date

    Mpox PCR positivity in participants with mpox infection symptoms

  2. Duration of general symptoms

    Time frame: From 14 days after the index date to twelve months after the index date

    Time from onset to resolution of general symptoms in participants with PCR-confirmed mpox infection (in days).

  3. Severity of rash

    Time frame: From 14 days after the index date to twelve months after the index date

    Number of mpox lesions (lesions count)

  4. Duration of skin rash

    Time frame: From 14 days after the index date to twelve months after the index date

    Time from onset to resolution of skin rash in participants with PCR-confirmed

  5. Medical treatment

    Time frame: From 14 days after the index date to twelve months after the index date

    Requirement of medical treatment (yes/no)

  6. Hospitalization

    Time frame: From 14 days after the index date to twelve months after the index date

    Requirement of hospital admission (yes/no)

  7. Scarring

    Time frame: From 14 days after the index date to twelve months after the index date

    Residual scarring after mpox (yes/no)

  8. Safety and tolerability

    Time frame: One month after vaccination

    Description of systemic and skin reactions

Sponsors and collaborators

Lead sponsor

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

Other

Collaborators

  • BCN Checkpoint
  • Centro de Salud Montesa
  • Centro de Saluld Sandoval
  • Department of Health, Generalitat de Catalunya
  • Fundación Arriaran
  • Germans Trias i Pujol Hospital
  • Harvard School of Public Health (HSPH)
  • Hospital Clinic of Barcelona
  • Hospital Nacional Arzobispo Loayza
  • Hospital Regional Docente de Trujillo
  • Hospital Regional III Honorio Delgado
  • Hospital Universitario 12 de Octubre
  • Hospital Vall d'Hebron
  • Instituto Conmemorativo Gorgas de Estudios de la Salud
  • London School of Hygiene and Tropical Medicine
  • Madrid Salud
  • Ministerio de Salud de Panamá
  • Public Health Service of Madrid

Registry information

Official study title

Break-through Infection Following Mpox vaccinatIon: Target Trial Emulation

Acronym: REMAIN

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Aug 31, 2022
Registry last updated
Jun 6, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.